Investigates the impact of tetrahedral framework nucleic acid-loaded sinomenine on inflammation in rheumatoid arthritis, suggesting improved treatment outcomes.
RA is an autoimmune joint disease, and sinomenine (SIN) treats RA but has low bioavailability. TFNA combines with SIN to improve delivery and inhibit inflammation for RA therapy.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: